Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.02.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Franziska Baatz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Department of Oncology and Blood Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Killer Cells, Natural, Lymphoid Progenitor Cells, Repressor Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Medizinischen Hochschule Hannover, German Research Foundation.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-induced suppression of the transcription factor B cell CLL/lymphoma 11B (BCL11B) propagates CAR-induced killer (CARiK) cell development from lymphoid progenitors. Here, we show that CRISPR-Cas9-mediated Bcl11b knockout in human and murine early lymphoid progenitors distinctively modulates this process either alone or in combination with a CAR. Upon adoptive transfer into hematopoietic stem cell recipients, Bcl11b-edited progenitors mediated innate-like antigen-independent anti-leukemic immune responses. With CAR expression allowing for additional antigen-specific responses, the progeny of double-edited lymphoid progenitors acquired prolonged anti-leukemic activity in vivo. These findings give important insights into how Bcl11b targeting can be used to tailor anti-leukemia functionality of CAR-engineered lymphoid progenitor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology, Department of Oncology and Blood Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medical Biotechnology, Technische Universität Braunschweig, Braunschweig, Germany.
- Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
- Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, Freiburg, Germany.
- Genome Analytics, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Förderung
- NCI NIH HHS
- Medizinischen Hochschule Hannover
- German Research Foundation
Zitieren
APA
Baatz, F., Ghosh, A., Herbst, J., Polten, S., Meyer, J., Rhiel, M., Maetzig, T., Geffers, R., Rothe, M., Bastone, A. L., John-Neek, P., Frühauf, J., Eiz-Vesper, B., Bonifacius, A., Falk, C. S., Kaisenberg, C. V., Cathomen, T., Schambach, A., van den Brink, M. R. M., …, & Sauer, M. G. (2025). Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.02.024
Vancouver
Baatz F, Ghosh A, Herbst J, Polten S, Meyer J, Rhiel M, et al. Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.02.024
BibTeX
@article{Baatz2025,
author = {Baatz, Franziska and Ghosh, Arnab and Herbst, Jessica and Polten, Saskia and Meyer, Johann and Rhiel, Manuel and Maetzig, Tobias and Geffers, Robert and Rothe, Michael and Bastone, Antonella Lucia and John-Neek, Philipp and Frühauf, Jörg and Eiz-Vesper, Britta and Bonifacius, Agnes and Falk, Christine S and Kaisenberg, Constantin V and Cathomen, Toni and Schambach, Axel and van den Brink, Marcel R M and Hust, Michael and Sauer, Martin G},
title = {Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.02.024}
}
EUVIMED